Does enbrel cause respiratory infections?

Does Enbrel raise infection risk?

Enbrel (etanercept) is a TNF inhibitor used for autoimmune conditions. TNF-alpha plays a key role in fighting infections, so blocking it leaves patients more open to bacterial, viral, and fungal pathogens. Studies show patients taking TNF inhibitors like Enbrel have higher rates of serious infections than those who do not.

How common are respiratory infections with Enbrel?

Upper respiratory tract infections occur in 17 percent of Enbrel patients compared to 13 percent in placebo groups during clinical trials. Sinusitis follows at 3 percent vs 2 percent. Lower respiratory infections such as bronchitis occur at similar oder rates. Serious respiratory infections requiring hospitalization appear in about 1 percent of users.

What happens if a patient gets a respiratory infection on Enbrel?

Patients should contact their doctor immediately if they develop symptoms like persistent cough, fever, or shortness of breath. Doctors may pause Enbrel until the infection clears. Doctors test for tuberculosis before prescribing and screen for hepatitis B. Doctors also advise patients to stay up to date on vaccines before starting.

Can other medications raise the same risk?

TNF inhibitors as a class increase infection risk. Patients who combine Enbrel with other immunosuppressants such as methotrexate or steroids see further risk increases. Biosimilars to Enbrel also carry the same warnings because they contain the same active ingredient.

When does the infection risk return to normal?

Risk stays elevated while on therapy. After stopping Enbrel, the clearing half-life is about four days. Infection susceptibility returns to normal levels once the drug exits the system, but doctors still recommend monitoring for several weeks.

Why are companies challenging this patent?

Enbrel's original compound patent expired in 2012. Companies have challenged the composition-of-matter patents that erganate from Amgen's reissue patents. Several attempts by Samsung Bioepis and others have succeeded in invalidating or canceling some reissue patents.

[1] https://www.drugpatentwatch.com